

# Francesco Panzuto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8516759/publications.pdf>

Version: 2024-02-01

147  
papers

4,444  
citations

101496

36  
h-index

114418

63  
g-index

149  
all docs

149  
docs citations

149  
times ranked

4152  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. <i>Modern Pathology</i> , 2010, 23, 824-833.	2.9	396
2	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. <i>Endocrine-Related Cancer</i> , 2005, 12, 1083-1092.	1.6	360
3	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. <i>Journal of Clinical Oncology</i> , 2011, 29, 2372-2377.	0.8	261
4	Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. <i>Annals of Oncology</i> , 2008, 19, 903-908.	0.6	200
5	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 570-577.	0.5	158
6	Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. <i>European Journal of Cancer</i> , 2012, 48, 1608-1615.	1.3	149
7	Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. <i>Annals of Oncology</i> , 2006, 17, 461-466.	0.6	120
8	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 6-11.	1.8	104
9	Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate. <i>Neuroendocrinology</i> , 2012, 95, 207-213.	1.2	104
10	Prognosis of sporadic resected small (<math>\leq 2\text{ cm}</math>) nonfunctional pancreatic neuroendocrine tumors – a multi-institutional study. <i>Hpb</i> , 2018, 20, 251-259.	0.1	99
11	Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. <i>Endocrine-Related Cancer</i> , 2006, 13, 541-558.	1.6	98
12	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84
13	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
14	Endocrine tumours of the stomach. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 659-673.	1.0	72
15	Molecular pathology and genetics of pancreatic endocrine tumours. <i>Journal of Molecular Endocrinology</i> , 2012, 49, R37-R50.	1.1	70
16	SARS-CoV2 RNA detection in a pancreatic pseudocyst sample. <i>Pancreatology</i> , 2020, 20, 1011-1012.	0.5	59
17	Role of Combined [ $^{68}\text{Ga}$ ]Ga-DOTA-SST Analogues and [ $^{18}\text{F}$ ]FDG PET/CT in the Management of GEP-NENs: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 1032.	1.0	58
18	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2012, 96, 32-40.	1.2	55

#	ARTICLE	IF	CITATIONS
19	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
20	Everolimus in Pancreatic Neuroendocrine Carcinomas G3. <i>Pancreas</i> , 2017, 46, 302-305.	0.5	53
21	Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis. <i>Gastrointestinal Endoscopy</i> , 2004, 59, 766-771.	0.5	52
22	Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. <i>Endocrine-Related Cancer</i> , 2007, 14, 111-124.	1.6	52
23	Risk Factors for Sporadic Pancreatic Endocrine Tumors. <i>American Journal of Gastroenterology</i> , 2009, 104, 3034-3041.	0.2	52
24	Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas. <i>Neuroendocrinology</i> , 2009, 89, 223-230.	1.2	51
25	The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2014, 100, 293-299.	1.2	51
26	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1197-1205.	3.3	50
27	Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 663-670.	1.9	46
28	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
29	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. <i>PLoS ONE</i> , 2017, 12, e0179445.	1.1	45
30	Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. <i>Annals of Surgery</i> , 2020, 271, 527-533.	2.1	44
31	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , 2020, 27, 1348-1355.	0.7	44
32	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. <i>Oncologist</i> , 2017, 22, 409-415.	1.9	42
33	Gastric Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2004, 80, 16-19.	1.2	41
34	Clinical Usefulness of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Enteroâ€Pancreatic Neuroendocrine Neoplasms. <i>Oncologist</i> , 2018, 23, 186-192.	1.9	39
35	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3200-3206.	0.7	39
36	European Neuroendocrine Tumor Society (<sc>ENETS</sc>) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	39

#	ARTICLE	IF	CITATIONS
37	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 110-124.	2.0	36
38	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) <math>\leq 2\text{ cm}</math>: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020, 7, 598438.	1.2	33
39	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. <i>European Journal of Cancer</i> , 2021, 157, 403-414.	1.3	33
40	Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 1456-1460.	0.4	32
41	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
42	CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors. <i>Radiologia Medica</i> , 2022, 127, 691-701.	4.7	32
43	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology study Section of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , 2001, 33, 217-221.	0.4	29
44	Somatostatin receptor subtypes: basic pharmacology and tissue distribution. <i>Digestive and Liver Disease</i> , 2004, 36, S8-S16.	0.4	29
45	Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy. <i>Digestive and Liver Disease</i> , 2003, 35, 869-875.	0.4	28
46	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. <i>Neuroendocrinology</i> , 2016, 103, 531-537.	1.2	28
47	Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center. <i>Journal of Clinical Medicine</i> , 2019, 8, 910.	1.0	28
48	Nasogastric or nasointestinal feeding in severe acute pancreatitis. <i>World Journal of Gastroenterology</i> , 2010, 16, 3692.	1.4	28
49	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1486-1494.	1.8	27
50	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020, 25, 259-265.	1.9	27
51	Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. <i>Annals of Oncology</i> , 2003, 14, 586-591.	0.6	26
52	Corpus-predominant gastritis as a risk factor for false-negative $^{13}\text{C}$ -urea breath test results. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1453-1460.	1.9	26
53	Evaluation of the Relationships Between Computed Tomography Features, Pathological Findings, and Prognostic Risk Assessment in Gastrointestinal Stromal Tumors. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 271-278.	0.5	26
54	Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis. <i>Helicobacter</i> , 2003, 8, 300-306.	1.6	25

#	ARTICLE	IF	CITATIONS
55	Acute fulminant hepatitis E virus genotype 3e infection: Description of the first case in Europe. Scandinavian Journal of Infectious Diseases, 2014, 46, 727-731.	1.5	21
56	CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings. European Journal of Radiology, 2020, 124, 108812.	1.2	21
57	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
58	Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget, 2017, 8, 46624-46634.	0.8	20
59	Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges. Journal of Clinical Medicine, 2022, 11, 1461.	1.0	20
60	Peanut-Like 1 (Septin 5) Gene Expression in Normal and Neoplastic Human Endocrine Pancreas. Neuroendocrinology, 2005, 81, 311-321.	1.2	19
61	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
62	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 607-618.	1.6	18
63	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). Journal of Endocrinological Investigation, 2021, 44, 989-994.	1.8	18
64	Synoptic reporting of echocardiography in carcinoid heart disease (ENETS Carcinoid Heart Disease) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	16
65	Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre study. Digestive and Liver Disease, 2022, 54, 890-895.	0.4	16
66	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. Pancreatology, 2019, 19, 1067-1073.	0.5	15
67	Sporadic non-functioning pancreatic neuroendocrine tumours: multicentre analysis. British Journal of Surgery, 2021, 108, 811-816.	0.1	15
68	Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. Gastroenterology Research and Practice, 2021, 2021, 1-6.	0.7	15
69	Long-term octreotide treatment of metastatic carcinoid tumor. Annals of Oncology, 2000, 11, 491-494.	0.6	14
70	Digestive neuroendocrine neoplasms: A 2016 overview. Digestive and Liver Disease, 2016, 48, 829-835.	0.4	14
71	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1209-1224.	1.2	14
72	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs. <i>Pancreatology</i> , 2020, 20, 875-879.	0.5	14
74	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	1.2	13
75	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2227-2234.	1.8	13
76	Theranostic Designed Near-Infrared Fluorescent Poly (Lactic-co-Glycolic Acid) Nanoparticles and Preliminary Studies with Functionalized VEGF-Nanoparticles. <i>Journal of Clinical Medicine</i> , 2020, 9, 1750.	1.0	12
77	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021, 53, 367-374.	0.4	12
78	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
79	Rhabdomyolysis due to severe hypokaliemia in a Crohn's disease patient after budesonide treatment. <i>Digestive and Liver Disease</i> , 2007, 39, 776-779.	0.4	10
80	Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2002, 16, 855-859.	1.8	9
81	Abdominal tuberculosis with pancreatic involvement: a case report. <i>Digestive and Liver Disease</i> , 2003, 35, 283-287.	0.4	8
82	Oesophageal GIST: MDCT Findings of Two Cases and Review of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 481-485.	0.6	8
83	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781.	1.7	8
84	Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 383-386.	1.0	8
85	Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 484-490.	1.1	8
86	Prognostic significance of laterality in lung neuroendocrine tumors. <i>Endocrine</i> , 2022, 76, 733-746.	1.1	8
87	Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. <i>Digestive and Liver Disease</i> , 2010, 42, 457-458.	0.4	7
88	Novel Molecular Targets for the Treatment of Gastroenteropancreatic Endocrine Tumors: Answers and Unsolved Problems. <i>International Journal of Molecular Sciences</i> , 2013, 14, 30-45.	1.8	7
89	The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs. <i>Digestive and Liver Disease</i> , 2019, 51, 1725-1730.	0.4	7
90	MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells. <i>Neuroendocrinology</i> , 2021, 111, 739-751.	1.2	7

#	ARTICLE	IF	CITATIONS
91	Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 713.	1.0	6
92	Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series. <i>Journal of Clinical Medicine</i> , 2022, 11, 1641.	1.0	6
93	Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome. <i>Digestive and Liver Disease</i> , 2003, 35, 585-589.	0.4	5
94	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDORA Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1349-1351.	1.1	5
95	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1351.	1.0	5
96	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	0.6	5
97	Unlabelled somatostatin analogues in treatment of digestive endocrine tumours. <i>Digestive and Liver Disease</i> , 2004, 36, S42-S47.	0.4	4
98	Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 845-855.	0.6	4
99	Survival after active surveillance <i>versus</i> upfront surgery for incidental small pancreatic neuroendocrine tumours. <i>British Journal of Surgery</i> , 2022, 109, 733-738.	0.1	4
100	Clinical relevance of the expression of somatostatin receptors in digestive endocrine tumours. <i>Digestive and Liver Disease</i> , 2010, 42, 173-174.	0.4	3
101	A Case of Pancreatic Small Cell Neuroendocrine Carcinoma Associated With SIADH. <i>Pancreas</i> , 2016, 45, e20-e22.	0.5	3
102	What Gastroenterologists Should Know about Carcinoid Syndrome. <i>Gastroenterology Insights</i> , 2022, 13, 127-138.	0.7	3
103	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2658.	1.0	3
104	Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function. <i>Journal of Clinical Medicine</i> , 2022, 11, 3983.	1.0	3
105	[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 811-818.	1.8	2
106	Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. <i>Oncology Research and Treatment</i> , 2021, 44, 276-280.	0.8	2
107	Tumor Heterogeneity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. <i>Endocrines</i> , 2021, 2, 28-36.	0.4	2
108	Controversies in the treatment of digestive neuroendocrine tumors. <i>Journal of Cancer Metastasis and Treatment</i> , 2016, 2, 304.	0.5	2

#	ARTICLE	IF	CITATIONS
109	Phenotype Expression in a Case of Adult Cystic Fibrosis Caused by an Extremely Rare Compound Heterozygous Genotype (2183AA&gt;G/2789+5G&gt;A). <i>Pancreas</i> , 2009, 38, 599-601.	0.5	1
110	Sa1384 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms. <i>Gastroenterology</i> , 2016, 150, S301.	0.6	1
111	1179P Therapeutic sequences in advanced grade 1-2 pancreatic neuroendocrine tumours (pNET). <i>Annals of Oncology</i> , 2020, 31, S780.	0.6	1
112	1185P [18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia. <i>Annals of Oncology</i> , 2020, 31, S782.	0.6	1
113	Clinical Challenges in the Management of Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 257.	1.0	1
114	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4167-TPS4167.	0.8	1
115	Therapy of NET with radiolabeled SST analogs. , 2022, , .		1
116	667 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients. <i>Gastroenterology</i> , 2015, 148, S-128.	0.6	0
117	Reassessment of proliferative activity at disease progression in neuroendocrine neoplasms. <i>Annals of Oncology</i> , 2016, 27, vi143.	0.6	0
118	endocrine and neuroendocrine tumours 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasms. <i>Annals of Oncology</i> , 2016, 27, vi558.	0.6	0
119	P.02.4 REASSESSMENT OF HISTOLOGICAL FEATURES AT DISEASE PROGRESSION DURING THE FOLLOW-UP OF NEUROENDOCRINE TUMOURS. <i>Digestive and Liver Disease</i> , 2016, 48, e135.	0.4	0
120	Sa1389 Clinical Usefulness of Functional Imaging Tests in the Follow-Up of Digestive Neuroendocrine Neoplasms. <i>Gastroenterology</i> , 2016, 150, S302.	0.6	0
121	Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome. <i>Gastroenterology</i> , 2017, 152, S670.	0.6	0
122	Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms. <i>Gastroenterology</i> , 2017, 152, S669.	0.6	0
123	Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 219-234.		0
124	P.10.1 HETEROGENEITY OF DUODENAL NEUROENDOCRINE TUMORS: A MULTI-CENTRE EXPERIENCE IN ITALY. <i>Digestive and Liver Disease</i> , 2018, 50, e228.	0.4	0
125	P.04.10 PHOSPHORYLATED HISTONE H3 (PHH3) IS A NOVEL, INTERESTING PROGNOSTIC MARKER IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS. <i>Digestive and Liver Disease</i> , 2018, 50, e159.	0.4	0
126	Phosphorylated Histone H3 (PHH3) is a novel, interesting prognostic marker in GEP-NETs. <i>Pancreatology</i> , 2018, 18, S176-S177.	0.5	0



#	ARTICLE	IF	CITATIONS
127	P.03.1 PROGNOSTIC IMPACT OF TUMOR BURDEN IN STAGE IV NEUROENDOCRINE NEOPLASIA: COMPARISON BETWEEN PANCREATIC AND GASTROINTESTINAL LOCALIZATIONS. <i>Digestive and Liver Disease</i> , 2019, 51, e163.	0.4	0
128	P.03.12 TEXTURE ANALYSIS ON CONTRAST-ENHANCED COMPUTED TOMOGRAPHY IN LIVER METASTASES FROM PANCREATIC AND NON-PANCREATIC NEUROENDOCRINE NEOPLASIA. <i>Digestive and Liver Disease</i> , 2019, 51, e168-e169.	0.4	0
129	Prognosis of sporadic resected small (<math>\leq 2\text{ cm}</math>) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. <i>Hpb</i> , 2019, 21, S997.	0.1	0
130	Prognosis of sporadic resected small (<math>\leq 2\text{ cm}</math>) nonfunctional pancreatic neuroendocrine tumors - A multi-institutional study. <i>Hpb</i> , 2019, 21, S732-S733.	0.1	0
131	T03.01.11 INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES MYC-DRIVEN SECONDARY RESISTANCE TO EVEROLIMUS IN DIGESTIVE NETS. <i>Digestive and Liver Disease</i> , 2020, 52, S98-S99.	0.4	0
132	T03.01.15 SECOND PRIMARY NEOPLASMS IN PATIENTS WITH GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NEN): DATA FROM A RETROSPECTIVE IT.A.NET STUDY. <i>Digestive and Liver Disease</i> , 2020, 52, S100-S101.	0.4	0
133	955 INHIBITION OF CYCLIN DEPENDENT KINASES OVERCOMES MYC-DRIVEN SECONDARY RESISTANCE TO EVEROLIMUS IN DIGESTIVE NETS.. <i>Gastroenterology</i> , 2020, 158, S-195.	0.6	0
134	Treatment of Intestinal NETs (Including Appendix). , 2021, , 201-210.		0
135	Endoscopic Resection of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review. , 2021, 53, .		0
136	Reply to Dr. Hall and coworkers. Expert Opinion on Drug Safety, 2021, 20, 865-866.	1.0	0
137	AF.106 ROLE OF RADIOMICS IN THE EVEROLIMUS RESPONSE PREDICTION OF METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. <i>Digestive and Liver Disease</i> , 2021, 53, S186.	0.4	0
138	1111P New prognostic frontiers for lung neuroendocrine tumors: An Italian-Spanish multicentric study of 200 cases. <i>Annals of Oncology</i> , 2021, 32, S916.	0.6	0
139	AF.108 ROLE OF FDG PET IN THE MANAGEMENT OF GRADE 1 GASTROENTERO-PANCREATIC NEUROENDOCRINE NEOPLASIA. <i>Digestive and Liver Disease</i> , 2021, 53, S187.	0.4	0
140	OC.08.7 USEFULNESS OF 68-GALLIUM PET IN TYPE I GASTRIC NEUROENDOCRINE NEOPLASIA. <i>Digestive and Liver Disease</i> , 2021, 53, S126.	0.4	0
141	AF.20 REAL WORLD STUDY ON MANAGEMENT OF TYPE-I GASTRIC NEUROENDOCRINE NEOPLASMS: A SINGLE CENTER'S EXPERIENCE. <i>Digestive and Liver Disease</i> , 2021, 53, S146.	0.4	0
142	Abstract 3455: Functional imaging tests vs. computed tomography scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up. , 2015, , .		0
143	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. <i>Journal of Clinical Oncology</i> , 2016, 34, 219-219.	0.8	0
144	Endocrine-metabolic disorders in patients with gastroenteropancreatic and lung neuroendocrine tumors. <i>Endocrine Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
145	OC.03.6 DUODENAL GASTRIC METAPLASIA AND DUODENAL NEUROENDOCRINE NEOPLASMS: TRUE CAUSALITY OR SIMPLE COINCIDENCE?. Digestive and Liver Disease, 2022, 54, S76.	0.4	0
146	T.05.5 ANTIPROLIFERATIVE ACTIVITY OF HIGH DOSE SOMATOSTATIN ANALOGS IN GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Digestive and Liver Disease, 2022, 54, S134.	0.4	0
147	A Case Report of Multiple Gastrointestinal Stromal Tumors: Imaging Findings, Surgical Approach, and Review of the Literature. Frontiers in Surgery, 2022, 9, .	0.6	0